Mirum PharmaceuticalsMIRM
About: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Employees: 311
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 17
79% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 42
16% more call options, than puts
Call options by funds: $7.97M | Put options by funds: $6.87M
12% more capital invested
Capital invested by funds: $1.84B [Q2] → $2.07B (+$228M) [Q3]
11% more funds holding
Funds holding: 159 [Q2] → 176 (+17) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 9 (+0) [Q3]
3.13% less ownership
Funds ownership: 114.44% [Q2] → 111.31% (-3.13%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Ed Arce 51% 1-year accuracy 80 / 157 met price target | 52%upside $66 | Buy Reiterated | 13 Nov 2024 |
Citigroup David Lebowitz 45% 1-year accuracy 10 / 22 met price target | 57%upside $68 | Buy Maintained | 13 Nov 2024 |
Baird Brian Skorney 17% 1-year accuracy 4 / 24 met price target | 15%upside $50 | Outperform Maintained | 13 Nov 2024 |
Leerink Partners Mani Foroohar 29% 1-year accuracy 5 / 17 met price target | 13%upside $49 | Outperform Maintained | 17 Oct 2024 |
Financial journalist opinion
Based on 6 articles about MIRM published over the past 30 days
